Is Cisco (CSCO) Quietly Turning Its AI Security Push Into a Moat Around Enterprise Collaboration?

• In recent weeks, Tech Mahindra announced a partnership with Cisco to deliver an AI-driven Security Service Edge platform, while Intrado Life & Safety disclosed that its Emergency Routing Service is now integrated with Cisco-managed Webex Calling Multi-Tenant, enhancing cloud-based E911 compliance and safety for distributed workforces.
• These collaborations highlight how Cisco is embedding security and compliance deeper into its networking and collaboration platforms, potentially strengthening the appeal of its AI-ready infrastructure and cloud calling ecosystem for large, complex enterprise deployments.
• Next, we’ll examine how this AI-focused Security Service Edge partnership with Tech Mahindra could reshape Cisco’s investment narrative for long-term investors.

Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Cisco Systems Investment Narrative Recap

To own Cisco today, you have to believe it can turn its AI focused networking, security and collaboration stack into durable, recurring software and services revenue, while managing its dependence on big AI infrastructure orders from a small set of hyperscalers. The Tech Mahindra SSE partnership and Intrado Webex integration support Cisco’s AI and security story, but they do not materially change the near term catalyst around AI infrastructure demand or the key risk of order volatility.

Among the recent announcements, the Tech Mahindra AI driven Security Service Edge partnership is most relevant, because it reinforces Cisco’s push to embed cloud delivered security and zero trust into its networking footprint. If this offering scales, it could support the existing catalyst of higher margin security and software growth that complements AI hardware demand, while also testing Cisco’s ability to execute on new security platforms at the pace investors expect.

Yet even as these AI security wins build enthusiasm, investors still need to be aware of how concentrated AI infrastructure demand could...

Read the full narrative on Cisco Systems (it's free!)

Cisco Systems' narrative projects $77.0 billion revenue and $18.4 billion earnings by 2029. This requires 8.2% yearly revenue growth and a roughly $6.4 billion earnings increase from $12.0 billion today.

Uncover how Cisco Systems' forecasts yield a $130.23 fair value, a 8% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming Cisco could reach about US$81.3 billion in revenue and US$19.6 billion in earnings by 2029, which is a much more upbeat path than the consensus view. If you lean toward that camp, the new AI security and compliance deals might reinforce your belief in Cisco’s higher growth potential, but they could also shift how you think about risks like a possible slowdown in hyperscaler AI spending.

Explore 4 other fair value estimates on Cisco Systems - why the stock might be worth 9% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Cisco Systems research is our analysis highlighting 4 key rewards that could impact your investment decision.
• Our free Cisco Systems research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cisco Systems' overall financial health at a glance.

Curious About Other Options?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
• Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com